Celgene-partnered ArcherDX raises $35M to grow cancer test business | FierceBiotech
Mar 21, 2018 @ 11:57

ArcherDX has raised a $35 million series A round to grow its targeted sequencing assay business. The gene fusion detection specialist will use the money to grow its commercial operations in the U.S. and overseas while building out the companion diagnostic program that landed it a deal with Celgene.

Sourced through Scoop.it from: www.fiercebiotech.com

Leave a Reply